Charles Sigal
Director/Board Member at VIR BIOTECHNOLOGY, INC.
Net worth: 656 989 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dave Grayzel | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 10 years |
Phillip Sharp | M | 79 | 22 years | |
Robert Williams | M | 75 |
The J. David Gladstone Institutes
The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA.
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | 22 years |
Yvonne Greenstreet | M | 61 | 8 years | |
Vicki Sato | M | 75 | 18 years | |
Adrian Rawcliffe | M | 52 | 9 years | |
Phil Holzer | M | 48 | 11 years | |
Robert Perez | M | 59 | 7 years | |
Akshay Vaishnaw | M | 61 | 18 years | |
Brian Daniels | M | 65 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 24 years |
Jeremy Levin | M | 70 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 6 years |
Elliot Norry | M | 61 | 9 years | |
Dennis Ausiello | M | 78 |
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | 12 years |
Jeffrey Hatfield | M | 66 | 24 years | |
Marianne de Backer | M | 56 | - | |
Michael Bonney | M | 65 | 10 years | |
Ron Philip | M | - | 7 years | |
Noubar Afeyan | M | 60 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
John Furey | M | 59 | 8 years | |
George Scangos | M | 76 | 7 years | |
Robert Nelsen | M | 60 | 8 years | |
Amy Schulman | F | 63 | 10 years | |
Charles Albright | M | 66 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 16 years |
Nicholas Simon | M | 67 |
The J. David Gladstone Institutes
The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA. | - |
Jeffrey Poulton | M | 56 | 5 years | |
Rick Modi | M | 55 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Janet Napolitano | F | 65 | 4 years | |
Joshua Brodsky | M | - | 3 years | |
Marc Hurlbert | M | - |
Melanoma Research Alliance
| - |
Sung Lee | M | 53 | 1 years | |
Caroline Stout | F | 33 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Margaret Hamburg | M | 68 | 5 years | |
Jacob Rubens | M | - |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
Lawrence Alleva | M | 74 | 9 years | |
Sandra Leung | F | 63 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 16 years |
Kevin Fitzgerald | M | 56 | 19 years | |
Lynne Krummen | M | - | 6 years | |
Hari Pujar | M | - |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | 3 years |
Luk Vandenberghe | M | 47 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Jennifer Flaisher | F | - | 7 years | |
Carole Faig | F | 62 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Kimberly McCutcheon Jablonski | F | - | 21 years | |
Sona Saira Ramasastry | F | 48 | 5 years | |
Leon Black | M | 73 |
Melanoma Research Alliance
| - |
Michael Severino | M | 58 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | 2 years |
Timothy J. Maines | M | - | 7 years | |
Gerald Storch | M | 67 | 12 years | |
Sean Nolan | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Peter Kellogg | M | 67 | 1 years | |
Howard Liang | M | 60 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | 3 years |
Louis Schmukler | M | - | 13 years | |
Ed Mathers Mathers | M | 64 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Carlo de Notaristefani | M | 67 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 20 years |
Colleen Reitan | F | 64 | 6 years | |
Carolyn Bertozzi | M | 57 | 1 years | |
Ursula B. Bartels | F | 66 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 17 years |
Olivier Brandicourt | M | 68 | 4 years | |
Robert More | M | 56 | 8 years | |
David Pyott | M | 70 | 9 years | |
Kimberly Casiano | F | 67 | 14 years | |
Sara Nochur | M | 63 | 18 years | |
David T. Bonk | M | - |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 15 years |
Christine Regan Lindenboom | F | 43 | 9 years | |
Jeffrey Galik | M | - |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 15 years |
Geoffrey von Maltzahn | M | 43 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
Sancy Leachman | F | - |
Melanoma Research Alliance
| - |
Robert May | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Aaron Tward | M | - |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Robert E. Obana | M | - |
The J. David Gladstone Institutes
The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA. | - |
Warner C. Greene | M | - |
The J. David Gladstone Institutes
The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA. | - |
Melissa Moore | F | - |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
William S. Price | M | 68 |
The J. David Gladstone Institutes
The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA. | 8 years |
Stephen Garbacz | M | 65 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | 3 years |
Derica Rice | M | 59 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
Botond Roska | M | 54 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
James Cornelius | M | 81 | 12 years | |
Lamberto Andreotti | M | 73 | 19 years | |
Steven Altschuler | M | 70 | 10 years | |
Giovanni Caforio | M | 59 | 24 years | |
J. Goater | M | 48 | 6 years | |
Peter Jakobsen | M | 61 | 19 years | |
Peter R. Dolan | M | 68 | 18 years | |
Howard Horn | M | 47 | 6 years | |
Charles A. Heimbold | M | - | 20 years | |
Liisa I. Nogelo | F | 53 | - | |
Denice Torres | F | 64 | 2 years | |
Frederick Dale Fischer | M | 73 |
Purdue University
| 5 years |
Rogério Vivaldi Coelho | M | 60 | 2 years | |
Michael Grobstein | M | 81 | 13 years | |
Michel Martinus Gerardus Cup | M | 54 | 2 years | |
Jessica Fees | F | 52 | 8 years | |
Daniel Lynch | M | 65 | 21 years | |
Dominique M. Hanssens | M | - |
Purdue University
| 7 years |
Stephen W. Golsby | M | 69 | 13 years | |
James Noble | M | 65 | 15 years | |
Robert Singer | M | 72 | 8 years | |
Ramy Ibrahim | M | 49 | 11 years | |
Marsha Fanucci | F | 70 | 13 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 94 | 95.92% |
United Kingdom | 5 | 5.10% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Charles Sigal
- Personal Network